Raymond James Analysts Give IMV (IMV) a $10.00 Price Target

Raymond James set a $10.00 target price on IMV (NYSE:IMV) in a research note released on Thursday morning. The firm currently has an outperform rating on the stock.

Shares of IMV stock opened at $5.86 on Thursday. IMV has a 52 week low of $3.97 and a 52 week high of $7.21.

IMV (NYSE:IMV) last announced its earnings results on Friday, November 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.05 million.

A number of hedge funds and other institutional investors have recently made changes to their positions in IMV. CIBC World Markets Inc. bought a new stake in IMV during the second quarter valued at approximately $103,000. Renaissance Technologies LLC bought a new stake in IMV during the second quarter valued at approximately $230,000. Prentiss Smith & Co. Inc. grew its position in IMV by 1,929.0% during the third quarter. Prentiss Smith & Co. Inc. now owns 44,374 shares of the company’s stock valued at $264,000 after buying an additional 42,187 shares during the period. First Manhattan Co. bought a new stake in IMV during the third quarter valued at approximately $522,000. Finally, Intact Investment Management Inc. bought a new stake in IMV during the second quarter valued at approximately $1,611,000.

About IMV

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Read More: Understanding Relative Strength Index

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply